Oral HDAC Inhibitor Tucidinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Phase IIb Results

This multicenter Phase IIb study aimed to investigate the efficacy and safety of tucidinostat, 40 mg twice per week, in patients with relapsed/refractory peripheral T cell lymphoma.